Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23225456
PII: 32/12/5487
Knihovny.cz E-resources
- MeSH
- Hepatic Artery MeSH
- Adult MeSH
- Fluorouracil administration & dosage MeSH
- Infusions, Intra-Arterial MeSH
- Irinotecan MeSH
- Camptothecin administration & dosage analogs & derivatives MeSH
- Colorectal Neoplasms drug therapy pathology MeSH
- Leucovorin administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Liver Neoplasms drug therapy secondary MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fluorouracil MeSH
- Irinotecan MeSH
- Camptothecin MeSH
- Leucovorin MeSH
AIM: The aim of the present study was to evaluate single center experience with hepatic arterial infusion (HAI) of irinotecan, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma (CRC). PATIENTS AND METHODS: A retrospective analysis of 68 patients treated between 1998 and 2007 was performed. RESULTS: Among 60 patients who had no simultaneous liver-directed procedure (LDP), the best results obtained were complete response in two patients (3%), partial response in 18 patients (30%), and stable disease in 23 patients (38%), for an overall disease control rate of 72%. Median progression-free survival was 11 months, and median survival was 24 months. Overall survival was significantly better in patients with simultaneous LDP or secondary resection. Steatosis was present in all secondary resection specimens. CONCLUSION: Our data demonstrate the efficacy of HAI of irinotecan combined with 5-fluorouracil and leucovorin for liver metastases from CRC, specifically in patients also treated with LDP.
